---
title: "688137.SH (688137.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688137.SH/news.md"
symbol: "688137.SH"
name: "688137.SH"
parent: "https://longbridge.com/en/quote/688137.SH.md"
datetime: "2026-03-13T22:16:09.236Z"
locales:
  - [en](https://longbridge.com/en/quote/688137.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688137.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688137.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688137.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688137.SH/news.md)


# 688137.SH (688137.SH) — Related News

### [Novoprotein: Net profit loss of 76.1827 million yuan in 2025](https://longbridge.com/en/news/277179313.md)
*2026-02-27T10:15:04.000Z*
> Novoprotein released its performance report, achieving total operating revenue of 152 million yuan for the fiscal year 2

### [Dr. Peter Attia, an expert in the field of longevity, resigned from his position related to David Medical due to his association with Epstein](https://longbridge.com/en/news/274685424.md)
*2026-02-03T16:21:55.000Z*
> Dr. Peter Attia, an expert in the field of longevity, resigned from his position as Chief Scientific Officer of David Me

### [Novoprotein: Expected annual net profit loss of RMB 85 million to RMB -66 million in 2025](https://longbridge.com/en/news/274286967.md)
*2026-01-30T09:57:41.000Z*
> Novoprotein announced that it expects a net profit loss of between 85 million yuan and -66 million yuan for the year 202

### [](https://longbridge.com/en/news/273937989.md)
*2026-01-28T05:31:20.000Z*
> A-share pharmaceutical and medical stocks experienced volatile adjustments, with BeBetter Med falling nearly 15%. ACROBI

### [Novoprotein: Expected to repurchase shares worth 10 million to 20 million yuan, not yet initiated](https://longbridge.com/en/news/271412523.md)
*2026-01-04T07:49:37.000Z*
> Suzhou Novoprotein announced that the company's shareholder meeting on October 15, 2024, approved the share repurchase p

### [Novoprotein: Plans to repurchase shares worth 10 million to 20 million yuan, but has not yet started the buyback](https://longbridge.com/en/news/268206411.md)
*2025-12-02T08:29:10.000Z*
> Novoprotein announced that at the shareholders' meeting on October 15, 2024, the repurchase plan was approved, intending

### [Shareholders of Novoprotein plan to reduce their holdings by no more than 0.2%](https://longbridge.com/en/news/267665193.md)
*2025-11-27T09:49:04.000Z*
> Novoprotein announced that shareholders Nanjing Jinli, Suzhou Jinling, and Shanghai Pujin plan to reduce their holdings 

### [Novoprotein: Nanjing Jinli, Suzhou Jinling, and Shanghai Pujin plan to reduce their shareholdings](https://longbridge.com/en/news/267660006.md)
*2025-11-27T09:26:19.000Z*
> Novoprotein announced that shareholders Nanjing Jinli and Suzhou Jinling, holding a combined 0.0415% stake, plan to redu

### [Novoprotein: Shareholders reduced holdings by 314,100 shares](https://longbridge.com/en/news/260888775.md)
*2025-10-13T11:40:54.000Z*
> Novoprotein announced that shareholders Heze Qiaobei and Shanghai Pujin reduced their holdings by 162,000 shares and 152

### [Novoprotein: Net loss of 24.2236 million yuan in the first half of 2025](https://longbridge.com/en/news/254786036.md)
*2025-08-27T10:39:21.000Z*
> Novoprotein announced that its operating revenue in the first half of 2025 was 72.0946 million yuan, a year-on-year incr